DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 19-962/S-034

AstraZeneca LP
Attention: Ms. Paula Clark
1800 Concord Pile
P.O. Box 8355
Wilmington, DE 19803-8355

Dear Ms. Clark:

Please refer to your supplemental new drug application dated September 25, 2006, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Toprol XL (metoprolol succinate) extended release 25, 50, 100, and 200 mg Tablets.

This "Changes Being Effected" supplemental new drug application provides for revisions to the "PRECAUTIONS, Drug Interactions" and "ADVERSE REACTIONS, Post-Marketing Experience" sections of the approved package insert.

We have completed our review of this application. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text and with the minor editorial revisions listed below.

In the PRECAUTIONS/Drug Interactions section you proposed adding the following paragraph as the new third paragraph:

> Digitalis glycosides, in association with beta-blockers, may increase atrioventricular conduction time and may induce bradycardia.

This paragraph should read:

> Both digitalis glycosides and beta-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia.

Within 21 days of the date of this letter, submit content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/oc/datacouncil/spl.html, that is identical in content to the submitted labeling dated September 25, 2006 with the changes described above. Upon receipt and verification, we will transmit that version to the National Library of Medicine for public dissemination.

In addition, within 21 days of the date of this letter, amend any pending applications for this NDA with content of labeling in structured product labeling (SPL) format to include the changes approved in this application.

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Ms. Melissa Robb, Regulatory Health Project Manager, at (301) 796-1138.

Sincerely,

{See appended electronic signature page}

Norman Stockbridge, M.D., Ph.D.
Director
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Norman Stockbridge

3/14/2007 04:30:45 PM